Alpha radioligand therapies using lead-212 for cancer (lead candidate AB001)
| Date | Round | Amount |
|---|---|---|
| Jun 2023 | Seed Oslo-based ARTBIO raised a 23M USD seed led by F-Prime Capital and Omega Funds to develop its lead-212 radiopharmaceuticals for prostate cancer. | $23M |